Compare Sanofi SA (SNY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Spotify Technology — how do they compare? Sanofi SA trades at $43.62 (market cap $104.30B), while Spotify Technology trades at $488.14 (market cap $103.00B). The key difference: Sanofi SA and Spotify Technology are close in size by market cap, and Sanofi SA pays a 5.55% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| SNY | SPOT | |
|---|---|---|
Market Cap | $104.30B | $103.00B |
Sector | Health | Media |
52-Week High | $52.34 | $738.53 |
52-Week Low | $41.33 | $412.75 |
Enterprise Value | $124.19B | $92.70B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Spotify (SPOT) trades at $486.44, down 4.96% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $17.19B in 2025 and net income of $2.21B, with a record 300 million Premium subscribers in Q2 2026. Recent news highlights Spotify's initiative to label AI-generated artists for transparency, reflecting proactive content management.
The outlook remains positive with a consensus price target of $598.20, implying significant upside. Key risks include rising marketing and AI costs impacting margins, as seen in the Q2 2026 earnings miss. Investor sentiment is buoyed by subscriber growth and monetization efforts, but execution on cost control will be critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
